BeyondSpring  logo
BeyondSpring BYSI
$ 1.37 1.48%

Quarterly report 2025-Q3
added 02-21-2026

report update icon

BeyondSpring Accounts Payables 2011-2026 | BYSI

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.
Main types of accounts payable
Type of liabilityExample
To suppliers and contractorsGoods received but not yet paid for
Taxes and feesVAT, income tax, etc., not paid on time
SalariesEmployee wages not paid
To budgetsInsurance contributions to funds not paid
To foundersFounders provided borrowed funds
To banksOverdue loan payments
OtherFines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance
  1. Liquidity and solvency
    Accounts payable are part of short-term liabilities, so they affect liquidity ratios
  2. Financial stability
    The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
  3. Capital turnover
    Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
  4. Risks and reputation
    Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables BeyondSpring

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
295 K 561 K 1.08 M 1.66 M 2.22 M 2.54 M 9.59 M 3.38 M 444 K - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
9.59 M 295 K 2.42 M

Quarterly Accounts Payables BeyondSpring

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
304 K 266 K 358 K 295 K - - - - - - - 1.66 M 2.13 M 2.15 M 1.57 M 2.22 M 2.19 M 1.95 M 5.14 M 2.54 M 1.95 M 8.46 M 8.97 M 9.59 M - 2.8 M 4.39 M 3.38 M 1.02 M 2.03 M 1.01 M 444 K - - - 300 K - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
9.59 M 266 K 2.68 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer Accounts Payables Price % 24h Market Cap Country
I-Mab I-Mab
IMAB
570 M - - $ 866 M chinaChina
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
56.8 M $ 20.7 -1.24 % $ 2.61 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
3.24 M $ 0.84 7.59 % $ 4.58 M chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
65.5 M $ 166.38 1.52 % $ 8.28 B usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
183 K $ 26.86 -3.83 % $ 719 M usaUSA
Codexis Codexis
CDXS
2.84 M $ 1.02 0.99 % $ 74.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
1.61 M - - $ 86.2 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
3.46 M - 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
3.81 M - 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
4.29 M - - $ 2.17 B usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
1.98 M $ 3.13 -0.95 % $ 1.2 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
13.4 M - -24.86 % $ 820 K usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
10.7 M $ 41.6 -0.17 % $ 1.32 B usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
40.4 M $ 35.97 0.76 % $ 3.74 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
11.2 M $ 23.88 3.47 % $ 2.92 B usaUSA
Acasti Pharma Acasti Pharma
ACST
601 K - 4.01 % $ 150 M canadaCanada
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
3.18 M $ 8.35 -2.57 % $ 36.1 M usaUSA
Curis Curis
CRIS
3.02 M $ 1.08 -5.26 % $ 6.81 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
22.6 M $ 40.68 -1.02 % $ 3.83 B usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
1.52 M $ 17.89 -2.03 % $ 859 M usaUSA
Champions Oncology Champions Oncology
CSBR
4.25 M $ 6.07 2.71 % $ 82.9 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
4.93 M $ 0.72 -2.3 % $ 4.84 M usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
1.45 M $ 3.83 -10.09 % $ 244 M usaUSA
Daré Bioscience Daré Bioscience
DARE
1.46 M $ 1.61 -5.29 % $ 13.7 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
22 M $ 23.25 10.77 % $ 2.26 B franceFrance
AgeX Therapeutics AgeX Therapeutics
AGE
1.41 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
677 K - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
2.91 M - - $ 26.5 M usaUSA
Precision BioSciences Precision BioSciences
DTIL
2.97 M $ 4.33 3.1 % $ 16.6 M usaUSA
Agenus Agenus
AGEN
61.4 M $ 3.34 0.3 % $ 1.2 M usaUSA
Dyadic International Dyadic International
DYAI
656 K $ 0.77 -1.68 % $ 22.2 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
4.08 M - - $ 7.46 M israelIsrael
Editas Medicine Editas Medicine
EDIT
5.49 M $ 2.15 -2.27 % $ 177 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
9.03 M - - $ 3.67 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
18.4 M $ 29.2 -3.41 % $ 1.69 B usaUSA
Advaxis Advaxis
ADXS
6.08 M - -9.65 % $ 45.9 M usaUSA
Equillium Equillium
EQ
4.71 M $ 1.92 5.49 % $ 66.7 M usaUSA